JP2007517016A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517016A5
JP2007517016A5 JP2006546397A JP2006546397A JP2007517016A5 JP 2007517016 A5 JP2007517016 A5 JP 2007517016A5 JP 2006546397 A JP2006546397 A JP 2006546397A JP 2006546397 A JP2006546397 A JP 2006546397A JP 2007517016 A5 JP2007517016 A5 JP 2007517016A5
Authority
JP
Japan
Prior art keywords
drug
solid composition
composition according
particles
poloxamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006546397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/004287 external-priority patent/WO2005065657A2/en
Publication of JP2007517016A publication Critical patent/JP2007517016A/ja
Publication of JP2007517016A5 publication Critical patent/JP2007517016A5/ja
Abandoned legal-status Critical Current

Links

JP2006546397A 2003-12-31 2004-12-20 低溶解性薬剤及びポロキサマーの固体組成物 Abandoned JP2007517016A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53383603P 2003-12-31 2003-12-31
PCT/IB2004/004287 WO2005065657A2 (en) 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers

Publications (2)

Publication Number Publication Date
JP2007517016A JP2007517016A (ja) 2007-06-28
JP2007517016A5 true JP2007517016A5 (enExample) 2008-02-14

Family

ID=34748969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006546397A Abandoned JP2007517016A (ja) 2003-12-31 2004-12-20 低溶解性薬剤及びポロキサマーの固体組成物

Country Status (6)

Country Link
US (1) US8974823B2 (enExample)
EP (1) EP1701704A2 (enExample)
JP (1) JP2007517016A (enExample)
BR (1) BRPI0418330A (enExample)
CA (1) CA2548376A1 (enExample)
WO (1) WO2005065657A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
ES2377760T3 (es) * 2007-03-29 2012-03-30 F. Hoffmann-La Roche Ag Composición farmacéutica y proceso
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
SI2593463T1 (sl) * 2010-07-12 2020-10-30 Salix Pharmaceuticals, Inc. Formulacije rifaksimina in njihove uporabe
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
EP2770830A4 (en) * 2011-10-28 2015-05-27 Celgene Avilomics Res Inc METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
EP2825207B1 (en) 2012-03-16 2020-08-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
NZ741873A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
KR102154880B1 (ko) 2012-05-03 2020-09-10 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
HK1208377A1 (en) 2012-05-04 2016-03-04 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
JP5946798B2 (ja) * 2013-06-18 2016-07-06 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
JP5934677B2 (ja) * 2013-06-18 2016-06-15 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP6010060B2 (ja) * 2014-02-21 2016-10-19 住友ゴム工業株式会社 タイヤ用ゴム組成物、及び空気入りタイヤ
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
RU2639819C2 (ru) * 2014-12-30 2017-12-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Композиция, ингибирующая теломеразу
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN110072525B (zh) 2016-09-30 2022-12-02 萨利克斯药品公司 利福昔明的固态分散形式

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
DE69811233T2 (de) 1997-10-27 2003-11-20 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
CA2335620A1 (en) 1998-07-22 2000-02-03 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble nsaids
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE60017444T2 (de) 1999-11-12 2006-02-09 Abbott Laboratories, Abbott Park Pharmazeutische formulierungen auf basis fester dispersionen
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
NZ513964A (en) * 1999-12-08 2004-01-30 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
CZ20022047A3 (cs) 1999-12-23 2003-09-17 Pfizer Products Inc. Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva
JP2003521493A (ja) 2000-01-28 2003-07-15 スミスクライン・ビーチャム・コーポレイション 電気紡糸された医薬組成物
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
AR027656A1 (es) * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
AU5711501A (en) * 2000-04-20 2001-11-07 Rtp Pharma Inc Improved water-insoluble drug particle process
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0015239D0 (en) 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
DE10038571A1 (de) 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
KR20020014570A (ko) * 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
CN1255185C (zh) * 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AU2003214387A1 (en) * 2002-03-07 2003-09-16 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers

Similar Documents

Publication Publication Date Title
JP2007517016A5 (enExample)
ES2351947T3 (es) Formulaciones orales de liberacion controlada de un inhibidor de la enzima convertidora de interleucina-1-beta.
JP2011516612A5 (enExample)
NZ592719A (en) PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
CN104857515B (zh) 一种控释给药的药芯组合物以及包含该药芯组合物的渗透泵制剂
MXPA02001243A (es) Medios para crear una masa que tiene integridad estructural.
JP2009502487A5 (enExample)
JP2005515966A5 (enExample)
CN1503662A (zh) 药物制剂
JP2017532363A5 (enExample)
JP2013525394A (ja) 経口投与剤形
CN102548543B (zh) 具有改进的溶出率和最小的副作用的缓释的西洛他唑片剂
CN102525876B (zh) 阿司匹林固体分散体、其制备方法、药物组合物和用途
TW201110968A (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
JP2010536837A5 (enExample)
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
CN102580056B (zh) 一种含抗利尿成分的缓释注射剂及其制备方法
Saeed et al. Effect of natural/synthetic polymers and super disintegrants on the formulation of zafirlukast fast dissolving film
CN114533690B (zh) 含抗凝血药物西洛他唑的新制剂及其制备方法
JP2002512946A5 (enExample)
CN110946835A (zh) 一种利伐沙班固体分散片及其制备方法
BR112014026040B1 (pt) Comprimido de liberação sustentada que contém levodropropizina
TW201904572A (zh) 非布司他控釋組合物及其製備方法
CN103505421B (zh) 一种盐酸度洛西汀的肠溶微丸制剂
JP6156037B2 (ja) 固形医薬製剤組成物